GlaxoSmithKline has terminated its collaboration with Alector on experimental brain drugs, dealing a blow to the biotech's neuroscience ambitions. The decision follows clinical setbacks that derailed what was once a potentially $2.2 billion deal marking GSK's return to the field.
The alliance, announced in 2021, focused on developing monoclonal antibodies for neurodegenerative diseases like Alzheimer's. Alector had taken the lead on early-stage research, with GSK holding options to license candidates after Phase 1 trials.
Clinical setbacks proved decisive. GSK's decision aligns with a broader industry pattern of big pharma pulling back from high-risk neuroscience programs after disappointing trial data. The terminated pact does not include any upfront termination fees, according to Alector.
Alector's stock fell sharply on the news, reflecting investor concern about its pipeline without GSK's backing. The biotech now faces the challenge of advancing its remaining programs independently, while GSK shifts focus to other therapeutic areas.
Patients and clinicians may view the exit as another setback for Alzheimer's drug development. The field has seen several high-profile failures, though recent approvals of anti-amyloid antibodies have renewed some hope.